KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Liabilities (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Total Liabilities for 15 consecutive years, with $390.9 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 17.63% to $390.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $390.9 million through Dec 2025, up 17.63% year-over-year, with the annual reading at $390.9 million for FY2025, 17.63% up from the prior year.
  • Total Liabilities for Q4 2025 was $390.9 million at Supernus Pharmaceuticals, up from $370.1 million in the prior quarter.
  • The five-year high for Total Liabilities was $879.7 million in Q1 2023, with the low at $316.6 million in Q1 2025.
  • Average Total Liabilities over 5 years is $562.9 million, with a median of $382.9 million recorded in 2024.
  • The sharpest move saw Total Liabilities surged 30.62% in 2021, then tumbled 57.38% in 2024.
  • Over 5 years, Total Liabilities stood at $873.3 million in 2021, then decreased by 6.53% to $816.3 million in 2022, then crashed by 56.37% to $356.2 million in 2023, then dropped by 6.69% to $332.3 million in 2024, then grew by 17.63% to $390.9 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $390.9 million, $370.1 million, and $318.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.